Mablink
FranceWho owns Mablink?
Mablink is a French Biotech company, now owned by Eli Lilly, which acquired it in 2023 from UI Investissement and Turenne Groupe.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
- ·Fully exited in 2023 to Eli Lilly.
- ·Average hold across 2 realized cycles: 2 years.
Ownership history
2 ownership periods · co-invest detected
UI Investissement sold Mablink to Eli Lilly in 2023 after 2 years.
Turenne Groupe sold Mablink to Eli Lilly and Company in 2023 after 2 years.
More from Capital Santé 2
Other portfolio companies in the same fund.
More PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Mablink?
Mablink is now owned by Eli Lilly, which acquired it in 2023 from UI Investissement and Turenne Groupe.
When did Eli Lilly acquire Mablink?
Eli Lilly acquired Mablink in 2023, buying from UI Investissement and Turenne Groupe.
Who did Mablink sell to?
UI Investissement sold Mablink to Eli Lilly in 2023 (Trade Sale). Turenne Groupe sold Mablink to Eli Lilly and Company in 2023 (Trade Sale).
Who has owned Mablink over time?
Mablink has been through 2 private-equity ownership periods: UI Investissement · via UI Investissement · 2021–2023 · sold to Eli Lilly · (Trade Sale); Turenne Groupe · via Capital Santé 2 · 2021–2023 · sold to Eli Lilly and Company · (Trade Sale).